Lung injury is a hydrogen sulfide (H2S)-associated complication with high mortality in acute pancreatitis (AP) cases. Herein, we used Prussian Blue (PB) as a H2S-responsive acceptor to develop a novel pure-inorganic upconversion nanoprobe for detecting and eliminating H2S, which can be used for diagnosing AP and alleviating lung injury. Upconversion nanoprobes with 5 nm PB shells were optimized to achieve outstanding in vitro H2S detection capacity (linear range: 0-150 μM, LOD: 50 nM), which met the in vivo serum H2S range, and thus were feasible for imaging H2S in vivo. More importantly, when combined with the traditional H2S synthetase inhibitor dl-PAG, the nanoprobes also served as a therapeutic agent that synergistically alleviated lung injury. As PB is an FDA-approved drug, our work proposes a potential clinical modality for the early diagnosis of AP, which will decrease lung injury-induced mortality and increase the survival rates of AP cases.
Keyphrases
- photodynamic therapy
- fluorescence imaging
- transcription factor
- high resolution
- heavy metals
- energy transfer
- cardiovascular events
- aqueous solution
- risk factors
- drug induced
- risk assessment
- diabetic rats
- cardiovascular disease
- cancer therapy
- light emitting
- drug delivery
- tyrosine kinase
- solar cells
- drug administration
- quantum dots
- single molecule
- real time pcr
- adverse drug